COVID-19 Antiviral Sales Decrease 88%

Merck today announced financial results for the first quarter of 2023. In addition, Merck stated it realized lower sales of the oral COVID-19 antiviral Lagevrio™ (Molnupiravir), which decreased 88% to $392 million.

This decrease was primarily attributable to sales in the U.S. and U.K. markets in the first quarter of 2022 that did not recur in the first quarter of 2023.

LAGEVRIO's decline was also attributable to lower sales in Japan and Australia.

LAGEVRIO is approved or authorized for use in more than 25 countries. It helps reduce how sick people become when diagnosed with COVID‑19.

Additional COVID-19 antiviral news is posted at Coronavirus Today.